191 related articles for article (PubMed ID: 19148579)
1. Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.
Fayette J; Penel N; Chevreau C; Blay JY; Cupissol D; Thyss A; Guillemet C; Rios M; Rolland F; Fargeot P; Bay JO; Mathoulin-Pelissier S; Coindre JM; Bui-Nguyen B
Invest New Drugs; 2009 Oct; 27(5):482-9. PubMed ID: 19148579
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
Bui BN; Chevallier B; Chevreau C; Krakowski I; Peny AM; Thyss A; Maugard-Louboutin C; Cupissol D; Fargeot P; Bonichon F
J Clin Oncol; 1995 Oct; 13(10):2629-36. PubMed ID: 7595717
[TBL] [Abstract][Full Text] [Related]
4. [Effect of modified MAID regimen for patients with advanced soft tissue sarcoma].
Li EX; Zhang YT; Shang JT; Xu Z; Geng Y; Li SM; Shi F; Wu YY
Ai Zheng; 2006 Aug; 25(8):1048-51. PubMed ID: 16965692
[TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial.
Bui-Nguyen B; Ray-Coquard I; Chevreau C; Penel N; Bay JO; Coindre JM; Cupissol D; Italiano A; Bonichon F; Lotz JP; Thyss A; Jimenez M; Mathoulin-Pélissier S; Blay JY;
Ann Oncol; 2012 Mar; 23(3):777-784. PubMed ID: 21652583
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Santoro A; Tursz T; Mouridsen H; Verweij J; Steward W; Somers R; Buesa J; Casali P; Spooner D; Rankin E
J Clin Oncol; 1995 Jul; 13(7):1537-45. PubMed ID: 7602342
[TBL] [Abstract][Full Text] [Related]
7. Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas.
Pearl ML; Inagami M; McCauley DL; Valea FA; Chalas E; Fischer M
Int J Gynecol Cancer; 2002; 12(6):745-8. PubMed ID: 12445253
[TBL] [Abstract][Full Text] [Related]
8. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
Antman K; Crowley J; Balcerzak SP; Kempf RA; Weiss RB; Clamon GH; Baker LH
Cancer; 1998 Apr; 82(7):1288-95. PubMed ID: 9529020
[TBL] [Abstract][Full Text] [Related]
9. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma.
Verma S; Younus J; Stys-Norman D; Haynes AE; Blackstein M;
Cancer Treat Rev; 2008 Jun; 34(4):339-47. PubMed ID: 18313854
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
12. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH
J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890
[TBL] [Abstract][Full Text] [Related]
13. [Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
Huang YH; Wen XP; Hu L
Ai Zheng; 2002 Aug; 21(8):907-9. PubMed ID: 12478905
[TBL] [Abstract][Full Text] [Related]
14. Phase I-II trial of intensification of the MAID regimen with support of lenograstim (rHuG-CSF) in patients with advanced soft-tissue sarcoma (STS).
Chevreau C; Bui BN; Chevallier B; Krakowski I; Maugard C; Mihura J; Coindre JM; Gil B; Cour-Chabernaud V
Am J Clin Oncol; 1999 Jun; 22(3):267-72. PubMed ID: 10362334
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant and adjuvant chemotherapy with modified mesna, adriamycin, ifosfamide, and dacarbazine (MAID) regimen for adult high-grade non-small round cell soft tissue sarcomas.
Ogura K; Goto T; Imanishi J; Shinoda Y; Okuma T; Tsuda Y; Kobayashi H; Akiyama T; Hirata M; Yamamoto A; Kawano H
Int J Clin Oncol; 2013 Feb; 18(1):170-6. PubMed ID: 22179493
[TBL] [Abstract][Full Text] [Related]
16. Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma.
Elias A; Ryan L; Aisner J; Antman KH
Semin Oncol; 1990 Apr; 17(2 Suppl 4):41-9. PubMed ID: 2110385
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
D'Ambrosio L; Touati N; Blay JY; Grignani G; Flippot R; Czarnecka AM; Piperno-Neumann S; Martin-Broto J; Sanfilippo R; Katz D; Duffaud F; Vincenzi B; Stark DP; Mazzeo F; Tuchscherer A; Chevreau C; Sherriff J; Estival A; Litière S; Sents W; Ray-Coquard I; Tolomeo F; Le Cesne A; Rutkowski P; Stacchiotti S; Kasper B; Gelderblom H; Gronchi A;
Cancer; 2020 Jun; 126(11):2637-2647. PubMed ID: 32129883
[TBL] [Abstract][Full Text] [Related]
18. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Antman K; Crowley J; Balcerzak SP; Rivkin SE; Weiss GR; Elias A; Natale RB; Cooper RM; Barlogie B; Trump DL
J Clin Oncol; 1993 Jul; 11(7):1276-85. PubMed ID: 8315425
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas.
DeLaney TF; Spiro IJ; Suit HD; Gebhardt MC; Hornicek FJ; Mankin HJ; Rosenberg AL; Rosenthal DI; Miryousefi F; Ancukiewicz M; Harmon DC
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1117-27. PubMed ID: 12829150
[TBL] [Abstract][Full Text] [Related]
20. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
